\-\ Texto\\:\\ \ \(0\)\
\-\ unavailable\ \(26\)\
\-\ the\\ patient\\ is\\ followed\\ by\\ ent\\ with\\ plans\\ for\\ treatment\\ in\\ the\\ near\\ future\\ with\\ gamma\\ knife\\.\ \(0\)\
\-\ 5\\ mm\\ x\\ 9\\ mm\\ lesion\\ within\\ the\\ right\\ iac\\ which\\ demonstrates\\ isointense\\ signal\\ to\\ grey\\ matter\\ and\\ uniform\\ enhancement\\.\ \(0\)\
\-\ vestibular\\ \\(\\'acoustic\\'\\)\\ schwannoma\ \(0\)\
\-\ meningioma\ \(167\)\
\-\ epidermoid\ \(89\)\
\-\ schwannoma\\ \\(trigeminal\\,\\ vestibular\\,\\ etc\\.\\)\ \(0\)\
\-\ 47\\ year\\ old\\ female\\ with\\ long\\ term\\ hearing\\ loss\\ and\\ recent\\ disequilibrium\\ problems\\.\ \(1\)\
\-\ schwannomas\\ may\\ demonstrate\\ increased\\ signal\\ on\\ t2\\ weighted\\ sequences\\.\\ when\\ present\\,\\ this\\ is\\ due\\ to\\ the\\ presence\\ of\\ antoni\\ b\\ type\\ histology\\ which\\ is\\ characterized\\ by\\ looser\\ areolar\\ tissue\\ with\\ lower\\ cell\\ density\\ versus\\ antoni\\ a\\ histology\\ which\\ is\\ denser\\ and\\ more\\ cellular\\.\\ this\\ particular\\ lesion\\ does\\ not\\ show\\ does\\ not\\ show\\ hyperintensity\\,\\ and\\ therefore\\ would\\ be\\ expected\\ to\\ display\\ predominantly\\ antoni\\ a\\ histology\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ antoni\\:\\ 0\\.4681079418523479\ \(0\)\
\-\ histology\\:\\ 0\\.31067556560712545\ \(0\)\
\-\ vestibular\\:\\ 0\\.20128012128549394\ \(0\)\
\-\ schwannoma\\:\\ 0\\.16722755722419033\ \(0\)\
\-\ looser\\:\\ 0\\.14910070963792885\ \(0\)\
\-\ areolar\\:\\ 0\\.144180056569377\ \(0\)\
\-\ mm\\:\\ 0\\.13965213448049826\ \(0\)\
\-\ does\\:\\ 0\\.13490473352750568\ \(0\)\
\-\ disequilibrium\\:\\ 0\\.1346081179336247\ \(0\)\
\-\ which\\:\\ 0\\.13309841338733583\ \(0\)\
\-\ plans\\:\\ 0\\.13030951461033605\ \(0\)\
\-\ denser\\:\\ 0\\.13030951461033605\ \(0\)\
\-\ show\\:\\ 0\\.12387960803117135\ \(0\)\
\-\ schwannomas\\:\\ 0\\.11943125567033976\ \(0\)\
\-\ iac\\:\\ 0\\.11845359056226375\ \(0\)\
\-\ display\\:\\ 0\\.11581692290603192\ \(0\)\
\-\ cellular\\:\\ 0\\.11283469838938201\ \(0\)\
\-\ signal\\:\\ 0\\.11061953739048336\ \(0\)\
\-\ grey\\:\\ 0\\.10861228442516006\ \(0\)\
\-\ unavailable\\:\\ 0\\.10808595111786519\ \(0\)\
\-\ knife\\:\\ 0\\.10808595111786519\ \(0\)\
\-\ trigeminal\\:\\ 0\\.10808595111786519\ \(0\)\
\-\ is\\:\\ 0\\.1068810416110496\ \(0\)\
\-\ gamma\\:\\ 0\\.10522857739517794\ \(0\)\
\-\ ent\\:\\ 0\\.1039609988579596\ \(0\)\
\-\ uniform\\:\\ 0\\.10203712112176236\ \(0\)\
\-\ future\\:\\ 0\\.09786025840371441\ \(0\)\
\-\ hyperintensity\\:\\ 0\\.09729940544226245\ \(0\)\
\-\ etc\\:\\ 0\\.09597281195462182\ \(0\)\
\-\ particular\\:\\ 0\\.09522359074748259\ \(0\)\
\-\ lesion\\:\\ 0\\.09355464261992166\ \(0\)\
\-\ characterized\\:\\ 0\\.08964383928465398\ \(0\)\
\-\ 47\\:\\ 0\\.08946840715365548\ \(0\)\
\-\ hearing\\:\\ 0\\.08861726226784193\ \(0\)\
\-\ isointense\\:\\ 0\\.08828831976796211\ \(0\)\
\-\ expected\\:\\ 0\\.0879655841021627\ \(0\)\
\-\ versus\\:\\ 0\\.08629181142229483\ \(0\)\
\-\ therefore\\:\\ 0\\.0860043343556421\ \(0\)\
\-\ predominantly\\:\\ 0\\.08544348139419014\ \(0\)\
\-\ epidermoid\\:\\ 0\\.08476732684144905\ \(0\)\
\-\ problems\\:\\ 0\\.08463524523662862\ \(0\)\
\-\ by\\:\\ 0\\.08286792601712262\ \(0\)\
\-\ and\\:\\ 0\\.08064674381807911\ \(0\)\
\-\ near\\:\\ 0\\.07945344995316872\ \(0\)\
\-\ sequences\\:\\ 0\\.07805448400065619\ \(0\)\
\-\ the\\:\\ 0\\.07787515616665934\ \(0\)\
\-\ not\\:\\ 0\\.07703678294282562\ \(0\)\
\-\ term\\:\\ 0\\.07651404018435415\ \(0\)\
\-\ with\\:\\ 0\\.0764218548379174\ \(0\)\
\-\ matter\\:\\ 0\\.07429154489037053\ \(0\)\
\-\ to\\:\\ 0\\.07317707020874699\ \(0\)\
\-\ meningioma\\:\\ 0\\.07311145750467715\ \(0\)\
\-\ weighted\\:\\ 0\\.0727793211885563\ \(0\)\
\-\ presence\\:\\ 0\\.07010510251212856\ \(0\)\
\-\ would\\:\\ 0\\.06906814970923594\ \(0\)\
\-\ this\\:\\ 0\\.06705375121446921\ \(0\)\
\-\ recent\\:\\ 0\\.06606475627549124\ \(0\)\
\-\ followed\\:\\ 0\\.06588796418137134\ \(0\)\
\-\ type\\:\\ 0\\.0654538169449281\ \(0\)\
\-\ long\\:\\ 0\\.06469908497701651\ \(0\)\
\-\ density\\:\\ 0\\.06469908497701651\ \(0\)\
\-\ loss\\:\\ 0\\.05944333782325357\ \(0\)\
\-\ when\\:\\ 0\\.05893804268033052\ \(0\)\
\-\ enhancement\\:\\ 0\\.056159704928890726\ \(0\)\
\-\ t2\\:\\ 0\\.05613482567675258\ \(0\)\
\-\ due\\:\\ 0\\.05608517547402537\ \(0\)\
\-\ cell\\:\\ 0\\.05581464602281929\ \(0\)\
\-\ more\\:\\ 0\\.05357647212658048\ \(0\)\
\-\ increased\\:\\ 0\\.05276132114205017\ \(0\)\
\-\ tissue\\:\\ 0\\.051183124346218696\ \(0\)\
\-\ demonstrate\\:\\ 0\\.05072403927807789\ \(0\)\
\-\ present\\:\\ 0\\.050066435312427236\ \(0\)\
\-\ lower\\:\\ 0\\.049858475512667096\ \(0\)\
\-\ may\\:\\ 0\\.04910039799734106\ \(0\)\
\-\ demonstrates\\:\\ 0\\.04901820426479076\ \(0\)\
\-\ female\\:\\ 0\\.0470821186322582\ \(0\)\
\-\ treatment\\:\\ 0\\.0464778604392522\ \(0\)\
\-\ within\\:\\ 0\\.04493782244411526\ \(0\)\
\-\ be\\:\\ 0\\.03958032688889359\ \(0\)\
\-\ right\\:\\ 0\\.032348556218114145\ \(0\)\
\-\ patient\\:\\ 0\\.031734685834993615\ \(0\)\
\-\ year\\:\\ 0\\.030069212666466515\ \(0\)\
\-\ for\\:\\ 0\\.029572776852208972\ \(0\)\
\-\ on\\:\\ 0\\.029467873224826517\ \(0\)\
\-\ old\\:\\ 0\\.028876852876081043\ \(0\)\
\-\ in\\:\\ 0\\.024272297606911485\ \(0\)\
\-\ of\\:\\ 0\\.019094055016157057\ \(0\)\
